$2.31 Billion is the total value of Avoro Capital Advisors LLC's 32 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | IMMUNOMEDICS INC | $340,295,000 | +34.6% | 17,714,461 | 0.0% | 14.72% | -2.6% | |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $283,121,000 | +39.1% | 3,862,500 | -19.5% | 12.24% | +0.6% |
| ASND | Sell | ASCENDIS PHARMAsponsored adr | $211,272,000 | +70.3% | 1,795,000 | -9.3% | 9.14% | +23.2% |
| AMRN | Buy | AMARIN CORP PLCsponsored adr | $166,080,000 | +118.9% | 8,000,000 | +43.5% | 7.18% | +58.3% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $142,432,000 | +2.4% | 1,195,000 | -6.3% | 6.16% | -26.0% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $129,200,000 | +33.2% | 9,500,000 | -6.2% | 5.59% | -3.6% |
| HZNP | Sell | HORIZON PHARMA PLC | $105,720,000 | +24.4% | 4,000,000 | -8.0% | 4.57% | -10.0% |
| ZGNX | Sell | ZOGENIX INC | $105,344,000 | +46.3% | 1,915,000 | -3.0% | 4.56% | +5.8% |
| ARGX | Sell | ARGENX SEsponsored adr | $104,866,000 | +26.9% | 840,000 | -2.3% | 4.54% | -8.2% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $100,148,000 | +10.3% | 10,530,862 | +2.6% | 4.33% | -20.2% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $99,490,000 | -14.1% | 1,120,000 | -17.6% | 4.30% | -37.9% |
| TCDA | Sell | TRICIDA INC | $65,654,000 | +59.1% | 1,700,000 | -2.9% | 2.84% | +15.1% |
| MYOK | New | MYOKARDIA INC | $51,990,000 | – | 1,000,000 | +100.0% | 2.25% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $50,284,000 | +250.0% | 950,000 | +171.4% | 2.17% | +153.1% |
| ARRY | New | ARRAY BIOPHARMA INC | $48,760,000 | – | 2,000,000 | +100.0% | 2.11% | – |
| MDCO | New | MEDICINES CO | $43,658,000 | – | 1,562,000 | +100.0% | 1.89% | – |
| BDSI | Buy | BIODELIVERY SCIENCES INTL | $39,352,000 | +125.1% | 7,424,867 | +57.1% | 1.70% | +62.9% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $38,831,000 | +53.1% | 310,000 | +37.8% | 1.68% | +10.8% |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $35,576,000 | – | 1,325,000 | +100.0% | 1.54% | – |
| ALLO | Buy | ALLOGENE THERAPEUTICS INC | $29,793,000 | +7.4% | 1,128,594 | +0.0% | 1.29% | -22.4% |
| XENE | XENON PHARMACEUTICALS INC | $24,384,000 | +61.0% | 2,400,000 | 0.0% | 1.05% | +16.5% | |
| INTEC PHARMA LTD | $18,325,000 | -2.8% | 2,500,000 | 0.0% | 0.79% | -29.7% | ||
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $17,721,000 | -21.7% | 900,000 | -10.0% | 0.77% | -43.3% |
| PCRX | PACIRA PHARMACEUTICALS INC | $15,224,000 | -11.5% | 400,000 | 0.0% | 0.66% | -36.1% | |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC | $11,419,000 | -12.3% | 475,000 | 0.0% | 0.49% | -36.6% | |
| CBAY | New | CYMABAY THERAPEUTICS INC | $9,628,000 | – | 725,000 | +100.0% | 0.42% | – |
| ALIM | ALIMERA SCIENCES INC | $6,614,000 | +47.6% | 6,240,000 | 0.0% | 0.29% | +6.7% | |
| TLGT | Sell | TELIGENT INC | $6,068,000 | -16.4% | 5,231,206 | -1.3% | 0.26% | -39.6% |
| FENC | FENNEC PHARMACEUTICALS INC | $5,364,000 | -24.0% | 1,105,999 | 0.0% | 0.23% | -45.0% | |
| KOD | Sell | KODIAK SCIENCES INC | $4,094,000 | -36.1% | 627,021 | -30.5% | 0.18% | -53.8% |
| XBI | New | SPDR SERIES TRUST - S&P BIOTECHput | $1,270,000 | – | 1,000,000 | +100.0% | 0.06% | – |
| OTLK | Sell | OUTLOOK THERAPEUTICS INC | $630,000 | +85.3% | 84,999 | -87.5% | 0.03% | +35.0% |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INCcall | $0 | – | -50,000 | -100.0% | -0.00% | – |
| XBI | Exit | SPDR SERIES TRUST - S&P BIOTECHcall | $0 | – | -500,000 | -100.0% | -0.09% | – |
| Exit | PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $0 | – | -6,000,000 | -100.0% | -0.15% | – | |
| ACER | Exit | ACER THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.18% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -1,300,000 | -100.0% | -0.25% | – |
| YMAB | Exit | Y MABS THERAPEUTICS INC | $0 | – | -310,000 | -100.0% | -0.38% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -380,000 | -100.0% | -0.78% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -4,750,000 | -100.0% | -1.16% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -325,000 | -100.0% | -2.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.